Welcome!

News Feed Item

Orphan Diseases Partnering Terms and Agreements

LONDON, Aug. 27, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Orphan Diseases Partnering Terms and Agreements

https://www.reportbuyer.com/product/2043441/Orphan-Diseases-Partnering-Terms-and-Agreements.html

The Orphan Diseases Partnering Terms and Agreements report provides an understanding and access to the orphan diseases partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in orphan diseases partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Orphan diseases partnering contract documents
Top orphan diseases deals by value

The Orphan Diseases Partnering Terms and Agreements report provides an understanding and access to the orphan diseases partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an understanding and analysis of how and why companies enter orphan diseases partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors orphan diseases technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This report contains over 90 links to online copies of actual orphan diseases deals and where available, contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of orphan diseases dealmaking and business activities. Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in orphan diseases dealmaking since 2009 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.

Chapter 3 provides a review of the leading orphan diseases deals since 2009. Deals are listed by headline value, signed by big pharma and big biotech, most active bigpharma/bigbiotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapters 4 and 5 provide a comprehensive listing of the top 50 big pharma and big biotech companies with a brief summary followed by a comprehensive listing of orphan diseases deals, as well as contract documents available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 6 provides comprehensive access to all orphan diseases deals since 2009 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive directory of all orphan diseases partnering deals by specific therapeutic indication announced since 2009. The chapter is organized by specific orphan diseases therapeutic indication. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all orphan diseases partnering deals signed and announced since 2009. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in orphan diseases partnering and dealmaking since 2009.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of orphan diseases technologies and products.

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in orphan diseases dealmaking

2.1. Introduction
2.2. Orphan diseases partnering over the years
2.3. Big pharma orphan diseases dealmaking activity
2.4. Big biotech orphan diseases dealmaking activity
2.5. Most active in orphan diseases partnering
2.6. Orphan diseases partnering by deal type
2.7. Orphan diseases partnering by industry sector
2.8. Orphan diseases partnering by stage of development
2.9. Orphan diseases partnering by technology type
2.10. Average deal terms for orphan diseases
2.10.1 Orphan diseases headline values
2.10.2 Orphan diseases upfront payments
2.10.3 Orphan diseases milestone payments
2.10.4 Orphan diseases royalty rates

Chapter 3 - Leading orphan diseases deals

3.1. Introduction
3.2. Top orphan diseases deals by value

Chapter 4 - Big pharma orphan diseases deals

4.1. Introduction
4.2. How to use big pharma partnering deals
4.3. Big pharma orphan diseases partnering company profiles
Dainippon Sumitomo
Galderma
GlaxoSmithKline
Grifols
Kyowa Hakko Kirin
Mitsubishi Tanabe
Novartis
Pfizer
Sanofi
Shire
Shire Human Genetic Therapies
Takeda
Teva

Chapter 5 - Big biotech orphan diseases deals

5.1. Introduction
5.2. How to use big biotech partnering deals
5.3. Big biotech orphan diseases partnering company profiles
Acorda Therapeutics
Actelion
BioMarin Pharmaceuticals
Grifols
Ipsen
Isis Pharmaceuticals
Swedish Orphan Biovitrum
ViroPharma

Chapter 6 - Orphan diseases partnering contracts directory

6.1. Introduction

6.2. Company A-Z

Aradigm
Arbios Systems
BioMarin Pharmaceutical
Catalyst Pharmaceutical Partners
Cell Therapeutics
Chiesi Farmaceutici
Chroma Therapeutics
Edison Pharmaceuticals
EpiCept
Galderma
GlaxoSmithKline
GlycoMimetics
Grifols
Halozyme Therapeutics
HepaLife
Hyperion Therapeutics
Ikaria
Intellect Neurosciences
Isis Pharmaceuticals
Kyowa Hakko Kirin
Meda
NovaBay Pharmaceuticals
Orphan Therapeutics
Penwest Pharmaceuticals
Pfizer
S*Bio
Saint Louis University
Ucyclyd Pharma
Ultragenyx Pharmaceuticals
UniQure
Viropharma

6.3. By deal type

Asset purchase
Co-development
Collaborative R&D
Co-market
Development
Equity purchase
Licensing
Marketing
Option
Settlement
Supply

6.4. By stage of development

Discovery
Formulation
Marketed
Phase I
Phase II
Phase III
Preclinical
Regulatory

6.5. By technology type

Assays
Biological compounds
Biomaterials
Cell culture
Enabling technology
Gene therapy
Implant
Oligonucleotide
Peptides
RNA therapeutics
Screening
Small molecules
Stem cells

Chapter 7 - Orphan diseases dealmaking by therapeutic target

7.1. Introduction
7.2. Deals by therapeutic target
Orphan diseases

Appendices

Appendix 1 - Directory of orphan diseases deals by company A-Z 2009- Jan 2014
Appendix 2 - Directory of orphan diseases deals by deal type 2009- Jan 2014
Appendix 3 - Directory of orphan diseases deals by stage of development 2009-Jan 2014
Appendix 4 - Directory of orphan diseases deals by technology type 2009- Jan 2014
Appendix 5 - Partnering resource center

Online partnering
Partnering events
Further reading on dealmaking
Deal type definitions

About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering
Order Form - Therapy Reports

Table of figures

Figure 1: Orphan diseases partnering since 2009
Figure 2: Big pharma - top 50 - Orphan diseases deals 2009 to 2014
Figure 3: Big pharma orphan diseases deal frequency - 2009 to 2014
Figure 4: Big biotech - top 50 - Orphan diseases deals 2009 to Jan 2014
Figure 5: Big biotech orphan diseases deal frequency - 2009 to 2014
Figure 6: Active orphan diseases dealmaking activity- 2009 to 2014
Figure 7: Orphan diseases partnering by deal type since 2009
Figure 8: Orphan diseases partnering by industry sector since 2009
Figure 9: Orphan diseases partnering by stage of development since 2009
Figure 10: Orphan diseases partnering by technology type since 2009
Figure 11: Orphan diseases deals with a headline value
Figure 12: Orphan diseases deal headline value distribution, US$million - discovery stage
Figure 13: Orphan diseases deal headline value distribution, US$million - preclinical stage
Figure 14: Orphan diseases deal headline value distribution, US$million - phase I stage
Figure 15: Orphan diseases deal headline value distribution, US$million - phase II stage
Figure 16: Orphan diseases deal headline value distribution, US$million - phase III stage
Figure 17: Orphan diseases deal headline value distribution, US$million - regulatory stage
Figure 18: Orphan diseases deal headline value distribution, US$million - marketed stage
Figure 19: Summary median headline value by stage of development, 2009-2014
Figure 20 Orphan diseases deals with upfront payment values
Figure 21: Orphan diseases deal upfront payment distribution, US$million - discovery stage
Figure 22: Orphan diseases deal upfront payment distribution, US$million - preclinical stage
Figure 23: Orphan diseases deal upfront payment distribution, US$million - phase I stage
Figure 24: Orphan diseases deal upfront payment distribution, US$million - phase II stage
Figure 25: Orphan diseases deal upfront payment distribution, US$million - phase III stage
Figure 26: Orphan diseases deal upfront payment distribution, US$million - regulatory stage
Figure 27: Orphan diseases deal upfront payment distribution, US$million - marketed stage
Figure 28: Summary median upfront payments by stage of development, 2009-2014
Figure 29: Orphan diseases deals with milestone payments
Figure 30: Orphan diseases deal milestone distribution, US$million - discovery stage
Figure 31: Orphan diseases deal milestone distribution, US$million - preclinical stage
Figure 32: Orphan diseases deal milestone distribution, US$million - phase I stage
Figure 33: Orphan diseases deal milestone distribution, US$million - phase II stage
Figure 34: Orphan diseases deal milestone distribution, US$million - phase III stage
Figure 35: Orphan diseases deal milestone distribution, US$million - regulatory stage
Figure 36: Orphan diseases deal milestone distribution, US$million - marketed stage
Figure 37: Orphan diseases deals with royalty rates, %
Figure 38: Orphan diseases deal royalty rate distribution, US$million - discovery stage
Figure 39: Orphan diseases deal royalty rate distribution, US$million - preclinical stage
Figure 40: Orphan diseases deal royalty rate distribution, US$million - phase I stage
Figure 41: Orphan diseases deal royalty rate distribution, US$million - phase II stage
Figure 42: Orphan diseases deal royalty rate distribution, US$million - phase III stage
Figure 43: Orphan diseases deal royalty rate distribution, US$million - regulatory stage
Figure 44: Orphan diseases deal royalty rate distribution, US$million - marketed stage
Figure 45: Summary median royalty rate by stage of development, 2009-2014
Figure 46: Top orphan diseases deals by value since 2009
Figure 47: Online partnering resources
Figure 48: Forthcoming partnering events

Read the full report:
Orphan Diseases Partnering Terms and Agreements

https://www.reportbuyer.com/product/2043441/Orphan-Diseases-Partnering-Terms-and-Agreements.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Internet of @ThingsExpo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 21st Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The Internet of Things (IoT) is the most profound change in personal and enterprise IT since the creation of the Worldwide Web more than 20 years ago. All major researchers estimate there will be tens of billions devic...
Mobile device usage has increased exponentially during the past several years, as consumers rely on handhelds for everything from news and weather to banking and purchases. What can we expect in the next few years? The way in which we interact with our devices will fundamentally change, as businesses leverage Artificial Intelligence. We already see this taking shape as businesses leverage AI for cost savings and customer responsiveness. This trend will continue, as AI is used for more sophistica...
SYS-CON Events announced today that SourceForge has been named “Media Sponsor” of SYS-CON's 21st International Cloud Expo, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. SourceForge is the largest, most trusted destination for Open Source Software development, collaboration, discovery and download on the web serving over 32 million viewers, 150 million downloads and over 460,000 active development projects each and every month.
SYS-CON Events announced today that DXWorldExpo has been named “Global Sponsor” of SYS-CON's 21st International Cloud Expo, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Digital Transformation is the key issue driving the global enterprise IT business. Digital Transformation is most prominent among Global 2000 enterprises and government institutions.
One of the biggest challenges with adopting a DevOps mentality is: new applications are easily adapted to cloud-native, microservice-based, or containerized architectures - they can be built for them - but old applications need complex refactoring. On the other hand, these new technologies can require relearning or adapting new, oftentimes more complex, methodologies and tools to be ready for production. In his general session at @DevOpsSummit at 20th Cloud Expo, Chris Brown, Solutions Marketi...
In the world of DevOps there are ‘known good practices’ – aka ‘patterns’ – and ‘known bad practices’ – aka ‘anti-patterns.' Many of these patterns and anti-patterns have been developed from real world experience, especially by the early adopters of DevOps theory; but many are more feasible in theory than in practice, especially for more recent entrants to the DevOps scene. In this power panel at @DevOpsSummit at 18th Cloud Expo, moderated by DevOps Conference Chair Andi Mann, panelists discussed...
Elon Musk is among the notable industry figures who worries about the power of AI to destroy rather than help society. Mark Zuckerberg, on the other hand, embraces all that is going on. AI is most powerful when deployed across the vast networks being built for Internets of Things in the manufacturing, transportation and logistics, retail, healthcare, government and other sectors. Is AI transforming IoT for the good or the bad? Do we need to worry about its potential destructive power? Or will we...
Cloud-based disaster recovery is critical to any production environment and is a high priority for many enterprise organizations today. Nearly 40% of organizations have had to execute their BCDR plan due to a service disruption in the past two years. Zerto on IBM Cloud offer VMware and Microsoft customers simple, automated recovery of on-premise VMware and Microsoft workloads to IBM Cloud data centers.
Many organizations adopt DevOps to reduce cycle times and deliver software faster; some take on DevOps to drive higher quality and better end-user experience; others look to DevOps for a clearer line-of-sight to customers to drive better business impacts. In truth, these three foundations go together. In this power panel at @DevOpsSummit 21st Cloud Expo, moderated by DevOps Conference Co-Chair Andi Mann, industry experts will discuss how leading organizations build application success from all...
SYS-CON Events announced today that Daiya Industry will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Daiya Industry specializes in orthotic support systems and assistive devices with pneumatic artificial muscles in order to contribute to an extended healthy life expectancy. For more information, please visit https://www.daiyak...
SYS-CON Events announced today that SIGMA Corporation will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. uLaser flow inspection device from the Japanese top share to Global Standard! Then, make the best use of data to flip to next page. For more information, visit http://www.sigma-k.co.jp/en/.
The last two years has seen discussions about cloud computing evolve from the public / private / hybrid split to the reality that most enterprises will be creating a complex, multi-cloud strategy. Companies are wary of committing all of their resources to a single cloud, and instead are choosing to spread the risk – and the benefits – of cloud computing across multiple providers and internal infrastructures, as they follow their business needs. Will this approach be successful? How large is the ...
Your clients expect transactions to never fail, cloud access to be fast and always on, and their data to be protected - no exceptions. Hear about how Secure Service Container (SSC), an IBM-exclusive open technology, enables secure building and hosting of next-generation applications, both cloud and on-premises. SSC protects the full stack from external and insider threats, allows automatic encryption of data in-flight and at-rest, and is tamper-resistant during installation and runtime – with no...
With major technology companies and startups seriously embracing Cloud strategies, now is the perfect time to attend 21st Cloud Expo October 31 - November 2, 2017, at the Santa Clara Convention Center, CA, and June 12-14, 2018, at the Javits Center in New York City, NY, and learn what is going on, contribute to the discussions, and ensure that your enterprise is on the right path to Digital Transformation.
SYS-CON Events announced today that B2Cloud will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. B2Cloud specializes in IoT devices for preventive and predictive maintenance in any kind of equipment retrieving data like Energy consumption, working time, temperature, humidity, pressure, etc.